About 6 results found for searched term "HER2-IN-14" (0.122 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M42089 | HER2-IN-14 | EGFR/HER2 |
| HER2-IN-14 is an HER2 inhibitor with an IC50 of 18 nM. | ||
| M5307 | Afatinib dimaleate | EGFR/HER2 |
| BIBW 2992MA2; BIBW2992; Afatinib | ||
| Afatinib (BIBW2992) Dimaleate irreversibly inhibits EGFR/HER2 including EGFR(wt), EGFR(L858R), EGFR(L858R/T790M) and HER2 with IC50 of 0.5 nM, 0.4 nM, 10 nM and 14 nM, respectively; 100-fold more active against Gefitinib-resistant L858R-T790M EGFR mutant. | ||
| M6221 | Pertuzumab | EGFR/HER2 |
| Omnitarg, 2C4 | ||
| Pertuzumab, a humanized monoclonal antibody and the first in the class of agents called the HER2 dimerization inhibitors, impairs the ability of HER2 to bind to other members of the HER family, MW: 148 KD. | ||
| M7680 | PK 11195 | Parasite |
| RP 52028 | ||
| PK 11195 is a peripheral benzodiazepine antagonist. PK 11195 (RP 52028) is a ligand of translocator protein (TSPO), with IC50 values of 14.2 μM, 8.2 μM, 3.5 μM for L. amazonensis, L. major and L. braziliensis, respectively. | ||
| M27987 | CC214-2 | mTOR |
| CC214-2 is an oral active and selective mTOR kinase inhibitor. CC214-2 targets to both of mTORC1 (pS6) and mTORC2 (pAktS473). CC214-2 induces autophagy, which is a potential target for host-directed therapy (HDT) in tuberculosis. CC214-2 exhibits synergistic bactericidal and sterilizing activity agasinst tuberculosis (TB), and shortens the treatment duration. CC214-2 also inhibits Rapamycin-resistant signaling and the growth of glioblastomas in vitro and in vivo. | ||
| M29778 | MMT5-14 | Anti-infection |
| MMT5-14 is a remdesivir analogue with a higher antiviral activity in four variants of SARS-CoV-2 than Remdesivir. MMT5-14 inhibits SARS-CoV-2, α, β, γ and δ variants with EC50s of 0.4, 2.5, 15.9, 1.7 and 5.6 μM, respectively. MMT5-14 can be used for the research of COVID-19. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
